ClearPoint Neuro (ClearPoint Neuro) Debt-to-Equity : 0.66 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro Debt-to-Equity?

ClearPoint Neuro's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.42 Mil. ClearPoint Neuro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.52 Mil. ClearPoint Neuro's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $21.17 Mil. ClearPoint Neuro's debt to equity for the quarter that ended in Dec. 2023 was 0.66.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ClearPoint Neuro's Debt-to-Equity or its related term are showing as below:

CLPT' s Debt-to-Equity Range Over the Past 10 Years
Min: -76.91 Med: 0.43 Max: 10.15
Current: 0.66

During the past 13 years, the highest Debt-to-Equity Ratio of ClearPoint Neuro was 10.15. The lowest was -76.91. And the median was 0.43.

CLPT's Debt-to-Equity is ranked worse than
80.62% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs CLPT: 0.66

ClearPoint Neuro Debt-to-Equity Historical Data

The historical data trend for ClearPoint Neuro's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro Debt-to-Equity Chart

ClearPoint Neuro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.54

10.15

0.25

0.33

0.66

ClearPoint Neuro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.33	0.36	0.52	0.58	0.66

Competitive Comparison of ClearPoint Neuro's Debt-to-Equity

For the Medical Devices subindustry, ClearPoint Neuro's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ClearPoint Neuro's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's Debt-to-Equity falls into.

ClearPoint Neuro Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ClearPoint Neuro's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.424	+	13.517)	/	21.173
	=	0.66

ClearPoint Neuro's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.424	+	13.517)	/	21.173
	=	0.66

ClearPoint Neuro (NAS:CLPT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ClearPoint Neuro Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ClearPoint Neuro (ClearPoint Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075

Website

https://www.clearpointneuro.com

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.

Executives

Lynnette C Fallon	director	108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau	director	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra	officer: Chief Operating Officer	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett	director, officer: CEO and President	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall	officer: GM, Biologics & Drug Delivery	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro	officer: Vice President, Finance	5 MUSICK, IRVINE CA 92618
Harold A Hurwitz	officer: Chief Financial Officer
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R	director	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson	director	366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards	director	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc.	10 percent owner	75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners	officer: Vice President, Marketing	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103